Evidence map›Paper›PMID 33461383›Full record

ArticleThe Journal of international medical research2021

Analysis of drug resistance and mutation profiles in

Jie Zhang, Yixuan Ren, Liping Pan, Junli Yi, Tong Guan, Xinyu Yang, Zongde Zhang

Open access · goldAbstract read
In one paragraph

Article in The Journal of international medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Drug Resistance and Molecular Characteristics ofJournal of personalized medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jie ZhangBeijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID https://orcid.org/0000-0002-4780-8889
Yixuan RenCentral Laboratory, Beijing Research Institute for Tuberculosis Control, Beijing, China.
Liping PanBeijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Junli YiCentral Laboratory, Beijing Research Institute for Tuberculosis Control, Beijing, China.
Tong GuanDepartment of Tuberculosis, Huairou District Center for Diseases Control and Prevention, Beijing, China.
Xinyu YangCentral Laboratory, Beijing Research Institute for Tuberculosis Control, Beijing, China.
Zongde ZhangBeijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Capital Medical University · CNCenter for Tuberculosis Control of Guangdong Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study analyzed drug resistance and mutations profiles in

methodsThe proportion method was used to assess drug resistance profiles for four first-line and seven second-line anti-tuberculosis (TB) drugs. Molecular line probe assays were used for the rapid detection of resistance to rifampicin (RIF) and isoniazid (INH).

resultsAmong 235 strains of

conclusionOur results confirmed the high rate of drug-resistant TB, especially MDR-TB, in Huairou District, Beijing, China. Therefore, detailed drug testing is crucial in the evaluation of MDR-TB treatment.

Indexed as

Mycobacterium tuberculosisAntitubercular AgentsBacterial ProteinsBeijingChinaDrug ResistanceDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsMutationAntitubercular AgentsBacterial ProteinsisoniazidkatGline probe assaymultidrug-resistant tuberculosisMycobacterium tuberculosisphenotypic drug susceptibility testingrifampicinrpoB

Identifiers

PMID33461383
PMCPMC7818002
OpenAlexW3122914666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.